Summary of findings for the main comparison. Chronotherapy for the treatment of hyperlipidaemia.
| Chronotherapy for the treatment of hyperlipidaemia | ||||||
|
Participant or population: people with hyperlipidaemia
Settings: primary care
Intervention: evening statin dose Comparison: morning statin dose | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Morning statin dose | Evening statin dose | |||||
| Cardiovascular mortality | See comment | See comment | Not estimable | 0 (0) | See comment | Included RCTs did not report on this outcome |
| Cardiovacular morbidity | See comment | See comment | Not estimable | 0 (0) | See comment | Included RCTs did not report this outcome |
| At least 1 adverse event Follow‐up: mean 9 weeks | Study population | OR 0.71 (0.44 to 1.15) | 556 (5 studies) | ⊕⊕⊝⊝ low1,2 | ||
| 188 per 1000 | 141 per 1000 (92 to 210) | |||||
| Total Cholesterol (mg/dL) Follow‐up: mean 9 weeks | The mean total cholesterol (mg/dL) in the intervention groups was 4.33 higher (1.36 lower to 10.01 higher) | 514 (5 studies) | ⊕⊕⊝⊝ low1,2 | |||
| LDL‐C (mg/dL) Follow‐up: mean 9 weeks | The mean LDL‐C (mg/dL) in the intervention groups was 4.85 higher (0.87 lower to 10.57 higher) | 473 (5 studies) | ⊕⊕⊝⊝ low1,2 | |||
| HDL‐C (mg/dL) Follow‐up: mean 9 weeks | The mean HDL‐C (mg/dL) in the intervention groups was 0.54 higher (1.08 lower to 2.17 higher) | 514 (5 studies) | ⊕⊕⊝⊝ low1,2 | |||
| Triglycerides (mg/dL) Follow‐up: mean 9 weeks | The mean triglycerides (mg/dL) in the intervention groups was 8.91 lower (22 lower to 4.17 higher) | 510 (5 studies) | ⊕⊕⊝⊝ low1,2 | |||
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; OR: Odds ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Downgraded due to study limitations (unclear or high risk of bias) in the studies included. 2 Downgraded for imprecision due to very wide confidence interval.